.

Prostate Cancer Research Instutute

Announcements

  • Cabazitaxel, Jevtana Approved by FDA for metastatic HRPC previously treated with docetaxel.  read more
  • Provenge Approved by FDA for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  read more
  • 2010 Conference announced – Register Now! – Sept 11&12  REGISTER NOW Learn from the Experts Marriott Los Angeles Airport Hotel California, USA September 11-12, 2010   Speakers will include:   read more

What's New

  • Follow changes via Twitter “PCRIprostateLA”Follow changes via Twitter “PCRIprostateLA” read more
  • PCRI Website Undergoing Revision The PCRI.org website is currently undergoing major revisions. We appreciate your patience while we continue the upgrade.  Please direct comments to info@pcri.org. Thanks! read more

Latest Prostate Cancer News

Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Statins May Reduce Risk of Prostate Cancer Recurrence (7/2/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.

Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (6/30/2010)
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.

Jevtana Approved for Hormone-refractory Prostate Cancer (6/21/2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.

Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (6/8/2010)
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.


Copyright ©2005 CancerConsultants.com. All Rights Reserved.
Prostate Cancer News Archives »
 
September 11-12, 2010
Learn from the Experts